Samaritan Pharmaceuticals, Inc. is a development stage biotechnology company engaged in the research
and development of novel therapeutic and diagnostic products to treat chronic debilitating diseases such as AIDS, Alzheimer's,
Central Nervous System ("CNS") Disorders, Cancer, and Cardiovascular Disease.
Samaritan Pharmaceuticals, Inc. focuses on bridging University bright ideas through drug development,
thereby; creating a path for promising new innovative drugs to become commercially viable products. Samaritan's HIV
drug is the closest to commercialization, having completed Phase II human clinical trials, with significance in demonstrating
antiretroviral properties and improving quality of life. Samaritan plans to advance its’ HIV drug to Phase III trials
as soon as the FDA clears its proposed protocol. In addition, Samaritan is advancing a growing pipeline of future drugs
for AIDS, Alzheimer's, and Cardiovascular disease through preclinical trials, in preparation, for future growth, under its
collaboration with Georgetown University. Samaritan Research Laboratories at Georgetown University is the result of
a partnership with Georgetown University to develop a discovery Lab. Under the terms of its original agreement, Samaritan has licensed 12 technologies from Georgetown. The collaboration enables Samaritan
to receive exclusive rights to any results obtained from the collaboration research. Samaritan’s discovery lab
focuses on 4 areas: Alzheimer’s, HIV, Cancer and cardiovascular diseases. Alzheimer’s disease is the actual death
of brain cells. With current technology, the functions associated with brain cell death can never be regained. However,
Samaritan Pharmaceuticals’ stem cell therapy technology has demonstrated great promise in its ability to regenerate
these cells. Moreover, Samaritan has developed a treatment drug that appears to inhibit the progression of the disease.
Both of these technologies are revolutionary.
Samaritan’s HIV technology may be the solution to
the HIV epidemic. It is an easy to take, twice-a-day capsule that is well-tolerated in HIV-infected patients. It appears to
prevent the entry of the HIV virus into target cells by protecting the cells as opposed to combating the virus. As a significant
result, the virus does not develop resistance to the drug. The combination of superior efficacy, the inability of the virus
to confer resistance, and a favorable safety profile positions the drug as the treatment of choice.
In total, HIV medications could cost between $20,000 to
$30,000 per person annually. Moreover, a patient’s inability to tolerate the side effects of their HIV medication
leads to poor treatment compliance, which in turn may lead to drug resistance and treatment failure.
Samaritan
has developed a relatively affordable compound (pill) with little to no side affects. Additionally, the drug appears
to counteract resistance. Samaritan recently completed a Phase 2 clinical trial and is preparing to initiate a Phase 3 clinical
trial. Given the significant safety and efficacy of the technology, it is hoped that the pill may be available to the
public within a year.
Recently
Samaritan was listed on Larry Oakley’s stock picks on Wallstreet.com. It was also listed on Market Pulse AM Hot Stock
List.
Dr. Janet Greeson is CEO & President of Samaritan Pharmaceuticals,
Inc. She’s the author of "It’s Not What You’re Eating, It’s What’s Eating You" and "Food For
Love, Healing the Food, Sex, Love & Intimacy Relationship." She has also worked with Mother Theresa, and was the U.S.
Congressional Nominee for the State of Nevada in 1994.
To learn more about Samaritan Pharmaceuticals, Inc. please visit our website at www.samaritanpharma.com
